Anne Mieke Vandamme

Summary

Affiliation: University Hospitals Leuven
Country: Belgium

Publications

  1. ncbi European recommendations for the clinical use of HIV drug resistance testing: 2011 update
    Anne Mieke Vandamme
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
    AIDS Rev 13:77-108. 2011
  2. pmc Viral phylogeny in court: the unusual case of the Valencian anesthetist
    Anne Mieke Vandamme
    Laboratory for Clinical and Epidemiological Virology, Rega Institute for Medical Research, Department of Microbiology and Immunology, University of Leuven, Leuven, Belgium
    BMC Biol 11:83. 2013
  3. pmc HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics
    Ana B Abecasis
    Unidade de Saúde Pública Internacional e Bioestatística, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisboa, Portugal
    Retrovirology 10:7. 2013
  4. pmc Relating increasing hantavirus incidences to the changing climate: the mast connection
    Jan Clement
    Hantavirus Reference Center, Laboratory of Clinical Virology, Department of Microbiology and Immunology, Rega Institute, Minderbroedersstraat 10, B3000 Leuven, Belgium
    Int J Health Geogr 8:1. 2009
  5. ncbi Nonadherence to highly active antiretroviral therapy: clinically relevant patient categorization based on electronic event monitoring
    Eric Van Wijngaerden
    Department of Internal Medicine, University Hospitals of KU Leuven, Leuven, Belgium
    AIDS Res Hum Retroviruses 18:327-30. 2002
  6. ncbi A genotypic assay for the amplification and sequencing of gag and protease from diverse human immunodeficiency virus type 1 group M subtypes
    Kristel Van Laethem
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
    J Virol Methods 132:181-6. 2006
  7. doi Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006
    Jurgen Vercauteren
    Rega Institute for Medical Research and University Hospitals, Katholieke Universiteit Leuven, Leuven, Belgium
    AIDS Res Hum Retroviruses 24:355-62. 2008
  8. doi The rare HIV-1 gp41 mutations 43T and 50V elevate enfuvirtide resistance levels of common enfuvirtide resistance mutations that did not impact susceptibility to sifuvirtide
    Kris Covens
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
    Antiviral Res 86:253-60. 2010
  9. pmc env chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitors
    Valery Fikkert
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
    Antimicrob Agents Chemother 46:3954-62. 2002
  10. ncbi No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs
    Kristel Van Laethem
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium
    J Clin Virol 39:43-7. 2007

Detail Information

Publications74

  1. ncbi European recommendations for the clinical use of HIV drug resistance testing: 2011 update
    Anne Mieke Vandamme
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
    AIDS Rev 13:77-108. 2011
    ..Indeed, resistance test results should be used in the context of all other clinically relevant information for predicting therapy response...
  2. pmc Viral phylogeny in court: the unusual case of the Valencian anesthetist
    Anne Mieke Vandamme
    Laboratory for Clinical and Epidemiological Virology, Rega Institute for Medical Research, Department of Microbiology and Immunology, University of Leuven, Leuven, Belgium
    BMC Biol 11:83. 2013
    ..Their study illustrates the challenges and opportunities that arise from the use of phylogenetic inference in criminal trials concerning virus transmission...
  3. pmc HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics
    Ana B Abecasis
    Unidade de Saúde Pública Internacional e Bioestatística, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisboa, Portugal
    Retrovirology 10:7. 2013
    ..Sequence variation may affect antiviral drug resistance development, disease progression, evolutionary rates and transmission routes...
  4. pmc Relating increasing hantavirus incidences to the changing climate: the mast connection
    Jan Clement
    Hantavirus Reference Center, Laboratory of Clinical Virology, Department of Microbiology and Immunology, Rega Institute, Minderbroedersstraat 10, B3000 Leuven, Belgium
    Int J Health Geogr 8:1. 2009
    ..We also examined whether past temperature and precipitation preceding "mast years" were statistically linked to these NE outbreaks...
  5. ncbi Nonadherence to highly active antiretroviral therapy: clinically relevant patient categorization based on electronic event monitoring
    Eric Van Wijngaerden
    Department of Internal Medicine, University Hospitals of KU Leuven, Leuven, Belgium
    AIDS Res Hum Retroviruses 18:327-30. 2002
    ..0001) between the two groups. Adherent patients had a better outcome, as shown by a larger drop in viral load (p = 0.011) and rise in CD4+ cell count (p = 0.035), showing that the algorithm-based categorization is clinically relevant...
  6. ncbi A genotypic assay for the amplification and sequencing of gag and protease from diverse human immunodeficiency virus type 1 group M subtypes
    Kristel Van Laethem
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
    J Virol Methods 132:181-6. 2006
    ..The population sequences of the three other samples lacked a part of the sequence because of heterogeneous signal, probably due to the presence of quasi-species with insertions/deletions of a different length...
  7. doi Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006
    Jurgen Vercauteren
    Rega Institute for Medical Research and University Hospitals, Katholieke Universiteit Leuven, Leuven, Belgium
    AIDS Res Hum Retroviruses 24:355-62. 2008
    ..e., zidovudine, lamivudine, and efavirenz. Our results support the implementation of genotypic resistance testing as a standard of care in all treatment-naive patients in Belgium...
  8. doi The rare HIV-1 gp41 mutations 43T and 50V elevate enfuvirtide resistance levels of common enfuvirtide resistance mutations that did not impact susceptibility to sifuvirtide
    Kris Covens
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
    Antiviral Res 86:253-60. 2010
    ....
  9. pmc env chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitors
    Valery Fikkert
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
    Antimicrob Agents Chemother 46:3954-62. 2002
    ..In addition, we obtained a proof of principle that env CVT can become a helpful diagnostic tool in assessments of the phenotypic resistance of clinical HIV isolates to HIV entry inhibitors...
  10. ncbi No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs
    Kristel Van Laethem
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium
    J Clin Virol 39:43-7. 2007
    ..Resistance testing has been implemented into clinical guidelines as it has shown some beneficial effect on subsequent therapy response...
  11. pmc Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape
    Kristof Theys
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
    BMC Bioinformatics 11:409. 2010
    ..By simulation of evolution over this landscape, the individualized genetic barrier to NFV resistance may be estimated for an isolate...
  12. doi A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes
    Kristel Van Laethem
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
    J Virol Methods 153:176-81. 2008
    ..The relevance of these polymorphisms in the absence of the signature mutations remains unclear...
  13. ncbi Prevalence and origin of HIV-1 group M subtypes among patients attending a Belgian hospital in 1999
    Joke Snoeck
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B 3000, Belgium
    Virus Res 85:95-107. 2002
    ..The other non-B subtypes and the recombinants are mainly introduced by immigrants or by Belgian citizens traveling abroad...
  14. ncbi A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients
    Kristel Van Laethem
    Rega Institute for Medical Research and University Hospitals, Katholieke Universiteit Leuven, Belgium
    Antivir Ther 7:123-9. 2002
    ..The development of a genotypic drug resistance interpretation algorithm, and the evaluation of its power to predict therapy outcome...
  15. pmc Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event
    Leen Vijgen
    Laboratory of Clinical and Epidemiological Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Minderbroedersstraat 10, BE 3000 Leuven, Belgium
    J Virol 79:1595-604. 2005
    ....
  16. pmc Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent
    Joke Snoeck
    Rega Institute for Medical Research, Minderbroedersstraat 10, 3000 Leuven, Belgium
    Antimicrob Agents Chemother 50:694-701. 2006
    ..It is not yet known whether therapy response is subtype dependent, but the advice given to clinicians based on a genotypic interpretation algorithm differs according to the subtype...
  17. ncbi Complete genome sequence, taxonomic assignment, and comparative analysis of the untranslated regions of the Modoc virus, a flavivirus with no known vector
    Pieter Leyssen
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, B 3000 Leuven, Belgium
    Virology 293:125-40. 2002
    ..Also the putative secondary structure of circularized MODV RNA is presented...
  18. ncbi Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response
    Koen Deforche
    Rega Institute, Katholieke Universiteit Leuven, Leuven, Belgium
    Antivir Ther 13:399-407. 2008
    ..A method has been developed to estimate a fitness landscape experienced by HIV-1 under treatment selective pressure as a function of the genotypic sequence thereby also estimating the genetic barrier to resistance...
  19. doi Evolution of genotypic resistance to enfuvirtide in HIV-1 isolates from different group M subtypes
    Kris Covens
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
    J Clin Virol 44:325-8. 2009
    ..However, most studies include only subtype B strains, while it is known that especially the env region is very divergent among subtypes...
  20. ncbi Prevalence and correlates of nonadherence to antiretroviral therapy in a population of HIV patients using Medication Event Monitoring System
    Ann E Deschamps
    University Hospitals KU Leuven, Department of Internal Medicine, Leuven, Belgium
    AIDS Patient Care STDS 18:644-57. 2004
    ..04) than adherent patients. Identified correlates of nonadherence may help clinicians in detecting patients with HIV at risk for nonadherence and can support the development of adherence enhancing interventions...
  21. pmc The molecular population genetics of HIV-1 group O
    Philippe Lemey
    Rega Institute for Medical Research, KULeuven, B 3000 Leuven, Belgium
    Genetics 167:1059-68. 2004
    ..In addition, we show that evolutionary rate estimates for different HIV genes accurately reflect differential selective constraints along the HIV genome...
  22. ncbi Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G
    Ana Barroso Abecasis
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
    AIDS 19:1799-806. 2005
    ..To investigate whether and how mutations at position 89 of HIV-1 protease were associated with protease inhibitor (PI) failure, and what is the impact of the HIV-1 subtype...
  23. pmc Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients
    Kristof Theys
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
    Retrovirology 9:81. 2012
    ....
  24. pmc Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins
    Jan Balzarini
    Rega Institute for Medical Research, Gent, Belgium
    J Virol 78:10617-27. 2004
    ..The plant lectins represent a well-defined class of anti-HIV (microbicidal) drugs with a novel HIV drug resistance profile different from those of other existing anti-HIV drugs...
  25. pmc The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal
    Jurgen Vercauteren
    Rega Institute, Katholieke Universiteit Leuven, Leuven, Belgium
    Retrovirology 5:12. 2008
    ..5); and at the Fifth European HIV Drug Resistance Workshop, Cascais (Portugal), 28-30 March 2007 (Abstract 1)...
  26. pmc Analysis of the serotype and genotype correlation of VP1 and the 5' noncoding region in an epidemiological survey of the human enterovirus B species
    Inge Thoelen
    Laboratory of Clinical and Epidemiological Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium
    J Clin Microbiol 42:963-71. 2004
    ..g., primer choice), provided some background knowledge on the local spectrum of enteroviruses already exists...
  27. ncbi Performance of ViroSeq HIV-1 Genotyping System in routine practice at a Belgian clinical laboratory
    Bart Maes
    Clinical and Epidemiological Virology, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
    J Virol Methods 119:45-9. 2004
    ..3% of the cases where primer A failed. Most of these positive results were subtype B (74%). As a result of sequencing problems 65 out of 351 (18.5%) samples had to be processed with "in-house" procedures...
  28. doi Comparative performance of the REGA subtyping tool version 2 versus version 1
    Ana B Abecasis
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
    Infect Genet Evol 10:380-5. 2010
    ..The performance of the REGA HIV-1 subtyping tool was considerably improved from one version to the other. Our results are very valuable and allow us to make suggestions for further improvement of the tool for a version 3 release...
  29. pmc Recombination confounds the early evolutionary history of human immunodeficiency virus type 1: subtype G is a circulating recombinant form
    Ana B Abecasis
    Katholieke Universiteit Leuven, Laboratory for Clinical and Epidemiological Virology, AIDS Reference Laboratory, Rega Institute and University Hospitals, Minderbroedersstraat 10, B 3000 Leuven, Belgium
    J Virol 81:8543-51. 2007
    ..We suggest a reanalysis of all pure subtypes and CRFs in order to better understand how high rates of recombination have influenced HIV-1 evolutionary history...
  30. pmc Molecular evolution and circulation patterns of human respiratory syncytial virus subgroup a: positively selected sites in the attachment g glycoprotein
    Kalina T Zlateva
    Laboratory of Clinical and Epidemiological Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium
    J Virol 78:4675-83. 2004
    ..The evolutionary rate of HRSV subgroup A isolates was estimated to be 1.83 x 10(-3) nucleotide substitutions/site/year, projecting the most recent common ancestor back to the early 1940s...
  31. ncbi Rising prevalence of HIV-1 non-B subtypes in Belgium: 1983-2001
    Joke Snoeck
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
    J Acquir Immune Defic Syndr 35:279-85. 2004
    ....
  32. doi HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G
    Ana Carolina Palma
    Clinical and Epidemiological Virology, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
    J Antimicrob Chemother 67:1075-9. 2012
    ..The purpose of this study was the qualitative and quantitative assessment of the in vitro effect of HIV-1 protease (PR) mutation 82M on replication capacity and susceptibility to the eight clinically available PR inhibitors (PIs)...
  33. doi Transmission of drug-resistant HIV-1 is stabilizing in Europe
    Jurgen Vercauteren
    Katholieke Universiteit Leuven, Leuven, Belgium
    J Infect Dis 200:1503-8. 2009
    ..02). We found that TDR appears to be stabilizing in Europe, consistent with recent reports of decreasing drug resistance and improved viral suppression in patients treated for HIV-1 infection...
  34. ncbi Hepatitis C virus evolutionary patterns studied through analysis of full-genome sequences
    Marco Salemi
    Rega Institute for Medical Research, KULeuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
    J Mol Evol 54:62-70. 2002
    ..These results offer a general guideline for the future of HCV phylogenetic analysis and also provide important insights on HCV origin and evolution...
  35. doi HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure
    Raphael Z Sangeda
    Rega Institute for Medical Research, Department of Microbiology and Immunology, KU Leuven, 3000 Leuven, Belgium
    Infect Genet Evol 19:349-60. 2013
    ..The fitness landscapes have similar predictive power for treatment response under indinavir-containing regimen as standard rules-based algorithms, and additionally allow predicting genetic evolution under indinavir selective pressure...
  36. pmc Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response
    Jurgen Vercauteren
    Rega Institute for Medical Research, KU Leuven, Leuven, Belgium
    PLoS ONE 8:e61436. 2013
    ..Performance of the models was compared using the area under the ROC curve (AUC) and a Wilcoxon signed-rank test...
  37. ncbi Algorithms for the interpretation of HIV-1 genotypic drug resistance information
    Jurgen Vercauteren
    Clinical and Epidemiological Virology, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium
    Antiviral Res 71:335-42. 2006
    ..Successful therapy heavily relies on the expertise of the clinician...
  38. pmc Enhanced heterosexual transmission hypothesis for the origin of pandemic HIV-1
    João Dinis de Sousa
    Laboratory for Clinical and Epidemiological Virology, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven B 3000, Belgium
    Viruses 4:1950-83. 2012
    ..Our hypothesis does not exclude a role for parenteral transmission in the initial viral adaptation...
  39. doi Bayesian network analyses of resistance pathways against efavirenz and nevirapine
    Koen Deforche
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
    AIDS 22:2107-15. 2008
    ..To clarify the role of novel mutations selected by treatment with efavirenz or nevirapine, and investigate the influence of HIV-1 subtype on nonnucleoside reverse transcriptase inhibitor (nNRTI) resistance pathways...
  40. ncbi Evolutionary dynamics of human retroviruses investigated through full-genome scanning
    Philippe Lemey
    Rega Institute for Medical Research, KULeuven, Leuven, Belgium
    Mol Biol Evol 22:942-51. 2005
    ..Several evolutionary and statistical assumptions, examined using a Bayesian coalescent method, were shown to have little influence on our inference...
  41. ncbi Identification in gelada baboons (Theropithecus gelada) of a distinct simian T-cell lymphotropic virus type 3 with a broad range of Western blot reactivity
    Sonia Van Dooren
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
    J Gen Virol 85:507-19. 2004
    ....
  42. ncbi Complete genome sequence of Montana Myotis leukoencephalitis virus, phylogenetic analysis and comparative study of the 3' untranslated region of flaviviruses with no known vector
    Nathalie Charlier
    Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, Minderbroedersstraat 10, B 3000 Leuven, Belgium
    J Gen Virol 83:1875-85. 2002
    ..The availability of this latter sequence motif allows us to designate a virus as either an NKV or a vector-borne flavivirus...
  43. pmc Mosaic genomes of the six major primate lentivirus lineages revealed by phylogenetic analyses
    Marco Salemi
    Rega Institute for Medical Research, KULeuven, Leuven, Belgium
    J Virol 77:7202-13. 2003
    ..Our findings not only imply that the six so-called pure PLV lineages have in fact mosaic genomes but also make more unlikely the hypothesis of cospeciation of SIVs and their simian hosts...
  44. ncbi Full-genome analysis of a highly divergent simian T-cell lymphotropic virus type 1 strain in Macaca arctoides
    Sonia Van Dooren
    Laboratory for Clinical and Epidemiological Virology, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
    J Gen Virol 86:1953-9. 2005
    ..Full-genome molecular-clock analysis supports an archaic introduction of STLV-1 on the Asian continent, at least 269 000-156 000 years ago...
  45. pmc Genetic variability and molecular evolution of the human respiratory syncytial virus subgroup B attachment G protein
    Kalina T Zlateva
    Laboratory of Clinical and Epidemiological Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
    J Virol 79:9157-67. 2005
    ..HRSV-A and -B strains have similar phylodynamic patterns: both subgroups are characterized by global spatiotemporal strain dynamics, where the high infectiousness of HRSV permits the rapid geographic spread of novel strain variants...
  46. ncbi Interpreting resistance data for HIV-1 therapy management--know the limitations
    Kristel Van Laethem
    Clinical and Epidemiological Virology, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
    AIDS Rev 8:37-43. 2006
    ..All these analysis are of value, but still display some weak points. However, due to the fast evolving know-how in the field, a prospective trial in which different systems are compared head-to-head will be difficult to design...
  47. ncbi Lack of evidence for infection with simian immunodeficiency virus in bonobos
    Sonia Van Dooren
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
    AIDS Res Hum Retroviruses 18:213-6. 2002
  48. ncbi Mutations in both env and gag genes are required for HIV-1 resistance to the polysulfonic dendrimer SPL2923, as corroborated by chimeric virus technology
    Anke Hantson
    Laboratory for Molecular Virology, Molecular Medicine, Katholieke Universiteit Leuven, Flanders, Belgium
    Antivir Chem Chemother 16:253-66. 2005
    ..Phenotypic analysis of the NL4.3/SPL2923 p17- and p17/gp160-recombined strains indicated that the mutations in both env and gag have to be present to fully reproduce the resistance of NL4.3/SPL2923 towards SPL2923...
  49. pmc Simultaneous RNA quantification of human and retroviral genomes reveals intact interferon signaling in HTLV-1-infected CD4+ T cell lines
    Britta Moens
    Laboratory of Clinical and Epidemiological Virology, Rega Institute for Medical Research, KULeuven, Leuven, Belgium
    Virol J 9:171. 2012
    ....
  50. pmc Development and validation of a multiplex real-time PCR assay for simultaneous genotyping and human T-lymphotropic virus type 1, 2, and 3 proviral load determination
    Britta Moens
    Rega Institute for Medical Research, KU Leuven, Minderbroederstraat 10, 3000 Leuven, Belgium
    J Clin Microbiol 47:3682-91. 2009
    ..Moreover, our molecular assay could offer an alternative when current available serological assays are insufficient...
  51. doi CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis
    Soraya Maria Menezes
    Department of Microbiology and Immunology, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium
    J Neuroinflammation 11:18. 2014
    ..Although CD80 and CD86 costimulatory molecules play prominent roles in immune regulation and reflect disease status in multiple sclerosis (MS), data in HAM/TSP are lacking...
  52. ncbi A Bayesian statistical analysis of human T-cell lymphotropic virus evolutionary rates
    Philippe Lemey
    Rega Institute for Medical Research, Minderbroedersstraat 10, Katholieke Universiteit Leuven, B 3000 Leuven, Belgium
    Infect Genet Evol 5:291-8. 2005
    ..Statistical uncertainty burdens HTLV rate estimates based on both anthropological calibrations and on pedigree data; the former method rests on an untested assumption, whilst that latter is affected by small sample sizes...
  53. doi Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools
    Andrea Clemencia Pineda-Peña
    Laboratory for Clinical and Epidemiological Virology, Rega Institute for Medical Research, Department of Microbiology and Immunology, University of Leuven, Belgium Clinical and Molecular Infectious Diseases Group, Faculty of Sciences and Mathematics, Universidad del Rosario, Bogota, Colombia Electronic address
    Infect Genet Evol 19:337-48. 2013
    ..We also present the upgraded version 3 of the Rega HIV subtyping tool (REGAv3)...
  54. doi Diagnostic value of different adherence measures using electronic monitoring and virologic failure as reference standards
    Ann E Deschamps
    University Hospitals Leuven, Department of Internal Medicine, Katholieke Universiteit Leuven, Leuven, Belgium
    AIDS Patient Care STDS 22:735-43. 2008
    ..Combining the VAS with the SHCS-AQ seems a feasible nonadherence measure for daily clinical practice. Self-reports perform better after electronic monitoring: their diagnostic value could be lower when given independently...
  55. pmc The demise of multidrug-resistant HIV-1: the national time trend in Portugal
    Jurgen Vercauteren
    Department of Microbiology and Immunology, Minderbroedersstraat 10, 3000 Leuven, KU Leuven, Leuven, Belgium
    J Antimicrob Chemother 68:911-4. 2013
    ..Especially, multidrug-resistant viruses pose a threat to efficient therapy. We studied the changing prevalence of multidrug resistance (MDR) over time in a cohort of HIV-1-infected patients in Portugal...
  56. pmc RegaDB: community-driven data management and analysis for infectious diseases
    Pieter Libin
    Department of Microbiology and Immunology, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium
    Bioinformatics 29:1477-80. 2013
    ..Availability and implementation: Source code, binaries and documentation are available on http://rega.kuleuven.be/cev/regadb. RegaDB is written in the Java programming language, using a web-service-oriented architecture...
  57. doi Phylodynamics of the HIV-1 CRF02_AG clade in Cameroon
    Nuno R Faria
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
    Infect Genet Evol 12:453-60. 2012
    ....
  58. ncbi Estimating the relative contribution of dNTP pool imbalance and APOBEC3G/3F editing to HIV evolution in vivo
    Koen Deforche
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
    J Comput Biol 14:1105-14. 2007
    ....
  59. doi Evaluation of the automatic editing tool RECall for HIV-1 pol and V3 loop sequences
    Lore Vinken
    Clinical and Epidemiological Virology, Rega Institute for Medical Research, Department of Microbiology and Immunology, KU Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium
    J Virol Methods 193:135-9. 2013
    ..As differences in base calling have little impact on drug resistance interpretation and hands-on-time could be substantially reduced, RECall could be a valuable tool for the standardization and acceleration of the editing process. ..
  60. doi The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovir
    Kristof Theys
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
    Infect Genet Evol 9:683-8. 2009
    ..A number of TDF-based regimens are associated with high rate of early virological failure. In this study, we evaluated the impact of these combinations on K65R selection over time...
  61. ncbi Phylogenetic classification of TT virus groups based on the N22 region is unreliable
    Philippe Lemey
    Rega Institute for Medical Research, KULeuven, Minderbroedersstraat 10, B 3000, Belgium
    Virus Res 85:47-59. 2002
    ..We suggest that care should be taken in future TTV phylogenetic analysis, in particular, larger and more conserved regions should be sequenced to allow between group comparisons...
  62. pmc Novel recombinant virus assay for measuring susceptibility of human immunodeficiency virus type 1 group M subtypes to clinically approved drugs
    Kris Covens
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
    J Clin Microbiol 47:2232-42. 2009
    ....
  63. pmc Tracing the origin and history of the HIV-2 epidemic
    Philippe Lemey
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
    Proc Natl Acad Sci U S A 100:6588-92. 2003
    ....
  64. ncbi A combination of poor adherence and a low baseline susceptibility score is highly predictive for HAART failure
    Kristien van Vaerenbergh
    Rega Institute and University Hospitals, Katholieke Universiteit Leuven, Leuven, Belgium
    Antivir Chem Chemother 13:231-40. 2002
    ..Despite the presence of a limited number of baseline resistance mutations, perfectly adherent patients can control virus replication for a prolonged period...
  65. ncbi Mutations at 65 and 70 within the context of a Q151M cluster in human immunodeficiency virus type 1 reverse transcriptase impact the susceptibility to the different nucleoside reverse transcriptase inhibitors in distinct ways
    Kristel Van Laethem
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, and AIDS Reference Laboratory, University Hospitals Leuven, Leuven, Belgium
    Infect Genet Evol 7:600-3. 2007
    ..In vitro culturing in the presence of tenofovir resulted in further enhancement of phenotypic resistance levels towards tenofovir and nucleoside reverse transcriptase inhibitors due to the development of K65R...
  66. pmc A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export
    Dirk Daelemans
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, B 3000 Leuven, Belgium
    Proc Natl Acad Sci U S A 99:14440-5. 2002
    ..The reversibility of its binding to CRM1 and its availability through chemical synthesis could make it useful for studying CRM1-mediated export pathways...
  67. ncbi Circulation of genetically distinct contemporary human coronavirus OC43 strains
    Leen Vijgen
    Laboratory of Clinical and Epidemiological Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Belgium
    Virology 337:85-92. 2005
    ..We here describe specific characteristics associated with circulating HCoV-OC43 strains, and we provide substantial evidence for the genetic variability of HCoV-OC43...
  68. pmc High GUD incidence in the early 20 century created a particularly permissive time window for the origin and initial spread of epidemic HIV strains
    João Dinis de Sousa
    Laboratory for Clinical and Evolutionary Virology, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
    PLoS ONE 5:e9936. 2010
    ..Our results suggest that intense GUD in promiscuous urban communities was the main factor driving HIV emergence. Low circumcision rates may have played a role, probably by their indirect effects on GUD...
  69. pmc Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach
    Dimitrios Paraskevis
    Katholieke Universiteit Leuven, Rega Institute for Medical Research, Minderbroederstraat 10, B 3000 Leuven, Belgium
    Retrovirology 6:49. 2009
    ..However the spatial diffusion of the epidemic from the perspective of the virus has not previously been traced...
  70. pmc Ascorbic acid has superior ex vivo antiproliferative, cell death-inducing and immunomodulatory effects over IFN-α in HTLV-1-associated myelopathy
    Britta Moens
    Rega Institute for Medical Research, K U Leuven, Leuven, Belgium
    PLoS Negl Trop Dis 6:e1729. 2012
    ..Therefore, we performed the first comparative analysis of the ex vivo and in vitro molecular and cellular mechanisms of action of IFN-α and high-dose AA in HAM/TSP...
  71. pmc Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A
    Nuno R Faria
    Rega Institute, Katholieke Universiteit Leuven, Leuven, Belgium
    J Gen Virol 93:889-99. 2012
    ..We demonstrate that probabilistic models can uncover global patterns of HIV-2A dispersal providing sampling bias is taken into account and we provide a scenario for the international spread of this virus...
  72. ncbi Performance of the VERSANT HIV-1 resistance assays (LiPA) for detecting drug resistance in therapy-naive patients infected with different HIV-1 subtypes
    Inge Derdelinckx
    Rega Institute for Medical Research and University Hospitals, Katholieke Universiteit Leuven, Minderbroedersstraat 10, 3000, Leuven, Belgium
    FEMS Immunol Med Microbiol 39:119-24. 2003
    ..45% for RT; 6.85% for PRO) and minor discordances (4.13% for RT; 0.25% for PRO). Major discordances were rare (0.46% for RT; 0.12% for PRO). Indeterminate reactions were significantly associated with strains belonging to non-B subtypes...
  73. ncbi Phylogeny of primate T lymphotropic virus type 1 (PTLV-1) including various new Asian and African non-human primate strains
    Sonia Van Dooren
    Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B 3000 Leuven, Belgium
    Infect Genet Evol 7:374-81. 2007
    ..Barbary macaques, not yet described to be STLV-infected, carry a relatively recent acquired, typical African STLV-1, giving us no clue on the phylogeographical origin of PTLV-1...
  74. pmc DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A
    Lotte Coelmont
    Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium
    PLoS ONE 5:e13687. 2010
    ..Prolonged DEB025 treatment and multiple genotypic changes may be necessary to generate significant resistance to DEB025, underlying the high barrier to resistance...